Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a San Diego-based biopharmaceutical company specializing in the development and acquisition of technologies that support the discovery and development of new therapeutics. The company generates revenue by licensing its Captisol® platform to biotech partners and manages a diversified portfolio of over 100 licensed programs across various therapeutic areas and development stages. In July 2024, Ligand announced the acquisition of APEIRON Biologics AG for $100 million, securing royalty rights to the commercial oncology drug QARZIBA®, designed for the treatment of high-risk neuroblastoma. Financial results for the second quarter of 2024 showed revenues of $41.5 million, surpassing analysts' expectations. The company plans to release its fourth quarter and full-year 2024 financial results on February 27, 2025.